Jan Walewski

22.6k total citations · 5 hit papers
214 papers, 7.0k citations indexed

About

Jan Walewski is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jan Walewski has authored 214 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Pathology and Forensic Medicine, 89 papers in Oncology and 82 papers in Genetics. Recurrent topics in Jan Walewski's work include Lymphoma Diagnosis and Treatment (168 papers), Chronic Lymphocytic Leukemia Research (79 papers) and Viral-associated cancers and disorders (46 papers). Jan Walewski is often cited by papers focused on Lymphoma Diagnosis and Treatment (168 papers), Chronic Lymphocytic Leukemia Research (79 papers) and Viral-associated cancers and disorders (46 papers). Jan Walewski collaborates with scholars based in Poland, United States and United Kingdom. Jan Walewski's co-authors include Ruth Pettengell, Michael Pfreundschuh, Marco Ladetto, Matti Aapro, David Cameron, Julia Bohlius, Gary H. Lyman, Damien C. Weber, C. Zielinski and Andrew Jack and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jan Walewski

200 papers receiving 6.9k citations

Hit Papers

2010 update of EORTC guid... 2010 2026 2015 2020 2010 2015 2015 2017 2015 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    2010 777 citations Ruth Pettengell, Jan Walewski et al. profile →
  2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2015 611 citations Hervé Tilly, Andrew Jack et al. Annals of Oncology profile →
  3. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 477 citations Tamás Masszi, Jerzy Hołowiecki et al. profile →
  4. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 412 citations Elı́as Campo, Olivier Hermine et al. Annals of Oncology profile →
  5. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
    2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jan Walewski 4.6k 4.2k 1.9k 1.4k 913 214 7.0k
Éric Van Den Neste 5.5k 1.2× 4.2k 1.0× 2.0k 1.0× 1.6k 1.1× 926 1.0× 46 7.2k
David J. Straus 4.6k 1.0× 2.9k 0.7× 1.6k 0.8× 1.6k 1.2× 595 0.7× 175 6.5k
Michele Ghielmini 6.5k 1.4× 4.5k 1.1× 3.1k 1.6× 1.2k 0.8× 1.5k 1.6× 134 8.8k
Fredrick B. Hagemeister 6.1k 1.3× 4.3k 1.0× 2.7k 1.4× 1.6k 1.2× 1.1k 1.2× 257 8.5k
Félix Reyes 5.5k 1.2× 3.7k 0.9× 2.1k 1.1× 1.7k 1.2× 1.1k 1.2× 56 7.5k
Réda Bouabdallah 5.7k 1.2× 4.3k 1.0× 2.4k 1.2× 1.5k 1.1× 1.6k 1.7× 126 8.2k
Carol S. Portlock 4.2k 0.9× 2.7k 0.6× 1.5k 0.8× 1.4k 1.0× 534 0.6× 119 5.6k
Luis Fayad 6.3k 1.4× 5.5k 1.3× 2.7k 1.4× 1.3k 1.0× 1.7k 1.8× 334 9.7k
P Lederlin 5.1k 1.1× 3.3k 0.8× 2.0k 1.0× 1.9k 1.4× 795 0.9× 76 6.5k
Ariela Noy 4.5k 1.0× 3.3k 0.8× 1.5k 0.8× 1.6k 1.2× 522 0.6× 179 6.1k

Countries citing papers authored by Jan Walewski

Since Specialization
Citations

This map shows the geographic impact of Jan Walewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Walewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Walewski more than expected).

Fields of papers citing papers by Jan Walewski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Walewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Walewski. The network helps show where Jan Walewski may publish in the future.

Co-authorship network of co-authors of Jan Walewski

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Walewski. A scholar is included among the top collaborators of Jan Walewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Walewski. Jan Walewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Borowiec, Anna, Magdalena Rosińska, Beata Kotowicz, et al.. (2025). Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha. International Journal of Molecular Sciences. 26(9). 4071–4071. 2 indexed citations
2.
Borowiec, Anna, Magdalena Rosińska, Beata Kotowicz, et al.. (2025). Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study. Pharmaceuticals. 18(8). 1102–1102.
3.
Ayyappan, Sabarish, H. Miles Prince, Cecilia Carpio, et al.. (2024). Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study. Blood. 144(Supplement 1). 4486–4486.
4.
Paszkiewicz‐Kozik, Ewa, Sergiusz Markowicz, Jan Walewski, et al.. (2023). New molecular targets in Hodgkin and Reed-Sternberg cells. Frontiers in Immunology. 14. 7 indexed citations
5.
Borowiec, Anna, Magdalena Rosińska, Agnieszka Jagiełło-Gruszfeld, et al.. (2023). Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC study. PLoS ONE. 18(8). e0288146–e0288146. 7 indexed citations
6.
Walewski, Jan. (2021). Novel monoclonal antibodies for diffuse large B-cell lymphoma. Acta Haematologica Polonica. 52(4). 329–333. 2 indexed citations
7.
Paszkiewicz‐Kozik, Ewa, Agnieszka Paziewska, Maria Kulecka, et al.. (2021). Peripheral Blood Cells from Patients with Hodgkin’s and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs. BioMed Research International. 2021(1). 3212878–3212878.
8.
Cheah, Chan Y., Wojciech Jurczak, Masa Lasica, et al.. (2021). TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma. HemaSphere. 286–286. 1 indexed citations
9.
Dreyling, Martin, Igor Aurer, Sergio Cortelazzo, et al.. (2017). Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia & lymphoma. 59(8). 1814–1828. 18 indexed citations
10.
Arcaini, Luca, Thierry Lamy, Jan Walewski, et al.. (2017). Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology. 180(2). 224–235. 9 indexed citations
11.
Paszkiewicz‐Kozik, Ewa, Monika Długosz‐Danecka, Paweł Robak, et al.. (2017). Subcutaneous Compared to Intravenous Administration of Rituximab Plus CHOP in Patients with Diffuse Large B-Cell Lymphoma — a Study By the Polish Lymphoma Research Group. Blood. 130. 5217–5217. 2 indexed citations
12.
O’Connor, Owen A., Steven M. Horwitz, Tamás Masszi, et al.. (2015). Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of Clinical Oncology. 33(23). 2492–2499. 386 indexed citations breakdown →
13.
Czyż, Anna, Joanna Drozd‐Sokołowska, Edyta Subocz, et al.. (2015). Early and late follow-up of patients with Hodgkin’s lymphoma. Recommendations of the Polish Lymphoma Research Group. Oncology in Clinical Practice. 11(6). 300–309. 1 indexed citations
14.
Sokołowska‐Wojdyło, Małgorzata, Aleksandra G. Florek, Jan Maciej Zaucha, et al.. (2014). Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. American Journal of Therapeutics. 23(3). e749–e756. 9 indexed citations
15.
16.
Kluin‐Nelemans, Hanneke C., Eva Hoster, Olivier Hermine, et al.. (2011). R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN: FIRST RESULTS OF A RANDOMIZED TRIAL FOR ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA. Annals of Oncology. 22. 86–86. 4 indexed citations
17.
Giebel, Sebastian, Jan Walewski, Elżbieta Nowara, et al.. (2010). Profilaktyka zajęcia ośrodkowego układu nerwowego u chorych na chłoniaka rozlanego z dużych komórek B. Rekomendacje Polskiej Grupy Badawczej Chłoniaków (PLRG). Nowotwory Journal of Oncology. 60(2). 161–161.
18.
Coiffier, Bertrand, Stéphane Leprêtre, Lars Møller Pedersen, et al.. (2007). Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 111(3). 1094–1100. 287 indexed citations
19.
Hancock, Bruno C., John Radford, M.H. Cullen, et al.. (2004). Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519).. British Journal of Cancer. 91. 1 indexed citations
20.
Marcus, Robert, Kevin Imrie, Andrew Belch, et al.. (2003). An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.. Ghent University Academic Bibliography (Ghent University). 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Éric Van Den Neste Breakdown of academic impact, for papers by David J. Straus Breakdown of academic impact, for papers by Michele Ghielmini Breakdown of academic impact, for papers by Fredrick B. Hagemeister Breakdown of academic impact, for papers by Félix Reyes Breakdown of academic impact, for papers by Réda Bouabdallah Breakdown of academic impact, for papers by Carol S. Portlock Breakdown of academic impact, for papers by Luis Fayad Breakdown of academic impact, for papers by P Lederlin Breakdown of academic impact, for papers by Ariela Noy
Rankless by CCL
2026